The Egyptian Drug Authority (EDA) has announced the completion of the specialized Good Manufacturing Practice (GMP) training program provided to its staff. The program was conducted in collaboration with the Biotech Training Facility (BTF) in the Netherlands, at the training center in Leiden – Netherlands, in addition to four online training modules delivered during November 2025. The training involved a number of specialists from the relevant departments, including:

The Central Administration for Biological, Innovative Products and Clinical Studies

The Central Administration for Pharmaceutical Establishments Inspection

The Central Administration for Pharmaceutical Establishments Licensing

This program comes as part of the Authority’s efforts to support its progress toward achieving Maturity Level 4 in line with the WHO Global Benchmarking Tool (GBT) methodology, and to promote compliance with WHO Good Regulatory Practices.

The training program aims to strengthen understanding of GMP requirements within a real operational environment, develop the capabilities of inspectors and technical assessors according to WHO and EU-GMP standards, and link GMP practices to the core indicators of the WHO-GBT, such as Licensing (LI), Regulatory Inspection (RI), Laboratory Testing (LT), and Lot Release (LR). It also supports the implementation of Maturity Level 4 practices, including dossier evaluation, laboratory oversight, inspections, and regulatory requirements.

The program underscores the EDA’s commitment to advancing regulatory practices and enhancing its readiness to achieve higher maturity levels in alignment with WHO standards. It also reflects the Authority’s dedication to building national capacities through international partnerships with specialized training institutions such as the Biotech Training Facility.